Lipid nanoparticle formulation of niclosamide (nano NCM) effectively inhibits SARS-CoV-2 replication
COVID-19
Lipid nanoparticle
SARS-CoV-2
niclosamide
Journal
Precision nanomedicine
ISSN: 2639-9431
Titre abrégé: Precis Nanomed
Pays: United States
ID NLM: 101735645
Informations de publication
Date de publication:
17 Apr 2021
17 Apr 2021
Historique:
entrez:
22
10
2021
pubmed:
23
10
2021
medline:
23
10
2021
Statut:
ppublish
Résumé
As exemplified by the COVID-19 pandemic, highly infective respiratory viruses can spread rapidly in the population because of lack of effective approaches to control viral replication and spread. Niclosamide (NCM) is an old anthelminthic drug (World Health Organization essential medicine list) with pleiotropic pharmacological activities. Several recent publications demonstrated that NCM has broad antiviral activities and potently inhibits viral replication, including replication of SARS-CoV-2, SARS-CoV, and dengue viruses. Unfortunately, NCM is almost completely insoluble in water, which limits its clinical use. We developed a cost-effective lipid nanoparticle formulation of NCM (nano NCM) using only FDA-approved excipient and demonstrated potency against SARS-CoV-2 infection in cells (Vero E6 and ACE2-expressing lung epithelium cells).
Identifiants
pubmed: 34676370
doi: 10.33218/001c.18813
pmc: PMC8528232
mid: NIHMS1693086
doi:
Types de publication
Journal Article
Langues
eng
Pagination
724-737Subventions
Organisme : NIAID NIH HHS
ID : R01 AI154959
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA194058
Pays : United States
Organisme : NIBIB NIH HHS
ID : R01 EB022040
Pays : United States
Organisme : NIH HHS
ID : S10 OD010366
Pays : United States
Références
Viruses. 2019 Feb 20;11(2):
pubmed: 30791609
Sci Rep. 2019 Jun 18;9(1):8682
pubmed: 31213630
Nanoscale. 2015 Apr 28;7(16):7127-32
pubmed: 25785368
Nature. 2020 Jul;583(7818):834-838
pubmed: 32408338
Nat Commun. 2019 Dec 18;10(1):5770
pubmed: 31852899
Proc Natl Acad Sci U S A. 2020 Jul 14;117(28):16587-16595
pubmed: 32571934
Sci Rep. 2018 Aug 24;8(1):12776
pubmed: 30143678
PLoS One. 2014 Jan 08;9(1):e85887
pubmed: 24416452
PLoS Pathog. 2012;8(10):e1002976
pubmed: 23133371
Artif Cells Nanomed Biotechnol. 2018 Dec;46(8):1926-1934
pubmed: 29113501
Nat Med. 2020 May;26(5):681-687
pubmed: 32327758
J Virol. 2005 Dec;79(24):15511-24
pubmed: 16306622
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
ACS Infect Dis. 2020 May 8;6(5):909-915
pubmed: 32125140
Antimicrob Agents Chemother. 2020 Jun 23;64(7):
pubmed: 32366720
PLoS One. 2013 Sep 03;8(9):e74670
pubmed: 24019973
Int J Pharm. 2018 Jan 15;535(1-2):157-163
pubmed: 29113805
Cell Host Microbe. 2020 Jul 8;28(1):124-133.e4
pubmed: 32485164
Nat Commun. 2018 Sep 26;9(1):3931
pubmed: 30258081
Crit Rev Ther Drug Carrier Syst. 2009;26(6):523-80
pubmed: 20402623
Cell Immunol. 2014 Mar-Apr;288(1-2):15-23
pubmed: 24561310
Cell. 2020 Jul 23;182(2):429-446.e14
pubmed: 32526206
Oncotarget. 2016 Feb 23;7(8):8993-9006
pubmed: 26848771
ACS Med Chem Lett. 2010 Sep 07;1(9):454-9
pubmed: 24900231
Antimicrob Agents Chemother. 2004 Jul;48(7):2693-6
pubmed: 15215127
J Virol. 2007 Jan;81(2):813-21
pubmed: 17079315
J Drug Target. 2015 Apr;23(3):222-31
pubmed: 25547369
PLoS One. 2018 Jun 1;13(6):e0198389
pubmed: 29856824
Cell. 2020 Jul 9;182(1):50-58.e8
pubmed: 32516571
Cell Signal. 2018 Jan;41:89-96
pubmed: 28389414
J Control Release. 2017 Sep 28;262:87-90
pubmed: 28713040
AAPS J. 2005 Sep 02;7(1):E241-8
pubmed: 16146345
J Microencapsul. 2015;32(5):496-502
pubmed: 26079596
Cancer Lett. 2014 Jul 10;349(1):8-14
pubmed: 24732808
Pharmacol Ther. 1982;19(2):245-95
pubmed: 6763710
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
Front Pharmacol. 2018 Jul 17;9:790
pubmed: 30065653